Sevelamer lowering effect on protein-bound uremic toxins in non-dialysis chronic kidney disease patients with hyperphosphatemia: A randomized controlled trial

Phase 3

Recruiting

• Conditions: - What effects does sevelamer have on serum p- cresol in non- dialysis chronic kidney disease patients with hyperphosphatemia?; Protein bound uremic toxin; p- cresol; indoxyl sulfate; Sevelamer; calcium carbonate

• Registration Number: TCTR20181018003
• Lead Sponsor: one

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-10-18
• Study Completion: 2019-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

1.Patients age 18 years old or older.
2.Non-dialysis patients who have eGFR < 60 ml/min/1.73m2 (Thai MDRD equation).
3.Hyperphosphatemia (> 5.0 mg/dL).

Exclusion Criteria

1.Existing or previous treatment with a phosphate binder within the last 1 month.
2.Recently adjust doses of vitamin D analogue within 3 months.
3.Patients with serum calcium more than 10.2 mg/dL.
4.Pregnancy
5.Patients who are unable to attend follow-up appointments.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
p-cresol 6 months HPLC

Secondary Outcome Measures

Name	Time	Method
indoxyl sulfate 6 months HPLC,renal function 6 months GFR (ml/min/1.73m2)